Experts from North American and European organisations are also supporting the trade mission. Anthony Davies, Ph.D., CEO of Dark Horse Consulting added, “As the first and only global consulting practice focused on CMC for cell and gene therapy, Dark Horse thoroughly endorses the intent of this trade mission. We also welcome the ISCT’s participation as a strategic partner. I look forward both to presenting our approach to navigating the challenges of manufacturing and regulating ATMPs, but also to listening to the concerns and aspirations of the Pacific Rim’s pioneers and participants in this field.”
Subscribe to our mailing list for the latest insights on advanced therapy development, regulatory updates, industry trends, and upcoming events from Dark Horse Consulting Group.
We respect your privacy. Unsubscribe at any time. We will never sell your information.